Nature Communications

Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial

2026-03-28

Full text

DOI https://doi.org/10.1038/s41467-026-71241-1